Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

March 10, 2026 updated by: Mayo Clinic

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the safety of personalized neoantigen peptide vaccine in combination with pembrolizumab in advanced solid cancers. (Phase I) II. To evaluate and estimate 24-months event-free survival (EFS) rate per Kaplan-Meier method in triple-negative breast cancer (TNBC) patients with residual cancer burden-2 and 3 (RCB-2 and RCB-3) after neoadjuvant pembrolizumab-based chemotherapy treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 3) III. To evaluate and estimate 24-months event-free survival (DFS) rate per Kaplan-Meier method in stage II/III non-small cell lung cancer (NSCLC) patients after surgery treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 4)

SECONDARY OBJECTIVES:

I. To evaluate and estimate the immunogenicity response rate in patients with advanced solid cancers receiving personalized neoantigen peptide vaccine in combination with pembrolizumab. (Phase I) II. To obtain preliminary information on the immunogenicity of neoantigen in induction of specific cellular immune responses and humoral immune response.

III. To evaluate and estimate the immunogenicity response rate in TNBC patients with residual cancer burden-2 and 3 (RCB-2 and RCB-3) after neoadjuvant pembrolizumab-based chemotherapy treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 3) IV. To evaluate adverse event profile in in TNBC patients with residual cancer burden-2 and 3 (RCB-2 and RCB-3) after neoadjuvant pembrolizumab-based chemotherapy treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 3) V. To evaluate and estimate the vaccine immunogenicity response rate in stage II/III NSCLC patients after surgery treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 4) VI. To evaluate adverse event profile in stage II/III NSCLC patients after surgery treated with neoantigen vaccine in combination with pembrolizumab. (Phase II Cohort 4)

EXPLORATORY OBJECTIVES:

I. To obtain preliminary information on the immunogenicity of neoantigen in induction of specific cellular immune responses and humoral immune response in patients with selected advanced solid tumors. (Phase I) II. To obtain preliminary estimates of efficacy as measured by objective response rate (ORR based on Response Evaluation Criteria in Solid Tumors [RECIST]) of personalized neoantigen peptide vaccine and pembrolizumab in patients with selected advanced solid tumors. (Phase I) III. To obtain preliminary information of immunity persistence, as well as pre-existing immunity in patients with selected advanced solid tumors. (Phase I) IV. To obtain preliminary information on the immunogenicity of neoantigen in induction of specific cellular immune responses and humoral immune response in Cohort 1 (TNBC patients with RCB-2 and RCB-3) and 2 (stage II/III NSCLC patients) separately. (Phase II) V. To obtain preliminary information of immunity persistence, as well as pre-existing immunity in Cohort 1 (TNBC patients with RCB-2 and RCB-3) and 2 (stage II/III NSCLC patients) separately. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of personalized neoantigen vaccine followed by a phase II study. Patients are assigned to 1 of 4 cohorts.

COHORT 1- *NO LONGER ENROLLING*: Patients receive cyclophosphamide intravenously (IV) on day -3. Patients then receive personalized neoantigen vaccine with sargramostim (GM-CSF) subcutaneously (SC) on days 1, 4, 8, and 15 of cycle 1 and on day 1 of cycle 2 in the absence of disease progression or unacceptable toxicity.

COHORT 2 - *NO LONGER ENROLLING*: Patients receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

COHORT 3: Patients with TNBC receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle or as clinically indicated. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

COHORT 4: Patients with NSCLC receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle or as clinically indicated. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

All patients may undergo tumor biopsy throughout the study. Additionally, patients undergo blood sample collection as well as computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.

After completion of study treatment, patients are followed up at 30 days and then every 3 months up to 2 years from study enrollment.

Study Type

Interventional

Enrollment (Estimated)

132

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Florida
      • Jacksonville, Florida, United States, 32224-9980
        • Recruiting
        • Mayo Clinic in Florida
        • Contact:
        • Principal Investigator:
          • Yanyan Lou, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria COHORT 1 and COHORT 2 are no longer enrolling.

PHASE I PRE-REGISTRATION, ALL:

  • Willing to provide tissue specimens per protocol

    • NOTE: includes fresh tissue specimen at pre-registration for complete exome and transcriptome sequencing. Patients who had tumor sequencing under certain Mayo Institutional Review Board (IRB) protocols and neoantigen has been identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration.

  • Measurable disease as defined by RECIST (version 1.1) criteria or non-measurable disease

    • NOTE: Tumor lesions in previously irradiated area are not considered measurable disease
  • Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have received and progressed on at least one line of prior FDA-approved targeted therapy
  • Provide written informed consent
  • Willing to return to enrolling institution for follow-up
  • Willing to provide blood specimens for research
  • Negative pregnancy test =< 7 days prior to pre-registration for persons of childbearing potential. If urine test cannot be confirmed negative, serum pregnancy test will be required.
  • Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle
  • Willing to receive tetanus vaccination if subject has not had one =< 1 year prior to pre-registration
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • Anticipated life expectancy > 6 months
  • Recovered from all toxicities associated with prior treatment to acceptable baseline status (see specified inclusion limits for laboratory toxicity) or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo).

  • The following lab values obtained =< 28 days prior to pre-registration:

    • Hemoglobin >= 9.0 g/dL (Must be >= 7 days after most recent transfusion)
    • Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 X 10^9/L
    • Platelet count >= 100,000/mm^3 or >= 100 X 10^9/L (Must be >=7 days after most recent transfusion)
    • Total bilirubin =< 1.5 x upper limit of normal (ULN)
    • Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3 x ULN or =< 5 x ULN with liver metastases
    • Creatinine =< 1.5 x ULN OR calculated creatinine clearance must be >= 50 ml/min using Cockcroft-Gault formula
    • International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy

PHASE I REGISTRATION, ALL:

  • Successful sequencing and production of REAL-Neo vaccine

  • Measurable disease as defined by RECIST (version 1.1) criteria or non-measurable disease

    • NOTE: Tumor lesions in previously irradiated area are not considered measurable disease
  • ECOG PS 0 or 1
  • Anticipated life expectancy > 6 months

  • The following lab values obtained =< 14 days prior to registration:

    • Hemoglobin >= 9.0 g/dl
    • ANC >= 1500/mm^3
    • Platelet count >= 100,000/mm^3
    • Total bilirubin =< 1.5 x ULN
    • ALT and AST =< 3 x ULN (=< 5 x ULN with liver involvement)
    • PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy
    • Calculated creatinine clearance >= 50 ml/min using Cockcroft-Gault formula
  • Provide written informed consent
  • Willing to provide blood and tissue specimens for research
  • Willing to return to enrolling institution for follow-up
  • Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy

  • Negative pregnancy test =< 14 days prior to registration for persons of childbearing potential only

    • NOTE: If urine test cannot be confirmed negative, serum pregnancy test will be required
  • Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle
  • Willing to receive tetanus vaccination if subject has not had one =< 1 year prior to pre-registration
  • Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicity see specified limits for inclusion) or NCI CTCAE version 5.0 Grade of 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo)

PHASE II PRE-SCREENING COHORT 3 ONLY:

  • ECOG PS 0 or 1
  • Histological confirmation of adenocarcinoma of the breast with estrogen receptor (ER) < 10%, progesterone receptor (PR) < 10%, and HER2 negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline
  • Stage I-III based on 7th edition of TNM staging system from American Joint Committee on Cancer (AJCC)
  • Evidence of residual disease >= 1 cm after neoadjuvant pembrolizumab-based chemotherapy on imaging for patients who have not had surgery
  • Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery
  • Provide written informed consent
  • Willing to return to enrolling institution for follow-up

PHASE II PRE-SCREENING COHORT 4 ONLY:

  • ECOG PS 0 or 1
  • Histological confirmation of lung NSCLC
  • No actionable EGFR mutations and ALK fusions
  • Stage II or stage III based on AJCC 8th
  • Tumor >= 2 cm on pre-surgery evaluation imaging (residual disease >= 2 cm after neoadjuvant therapy on pre-surgery evaluation imaging in patient who receives neoadjuvant therapy) for patients who have not had surgery. Patients with or without neoadjuvant chemotherapy or immunotherapy are allowed
  • Provide written informed consent
  • Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery
  • Willing to return to enrolling institution for follow-up

PHASE II PRE-REGISTRATION COHORT 3 (TNBC) ONLY:

  • Histologically confirmed residual cancer burden 2 and 3 in surgical specimens

PHASE II PRE-REGISTRATION COHORT 4 (NSCLC) ONLY:

  • Tumor without complete pathologic response is confirmed in pathology

  • Willing to proceed with surgery and provide tissue specimens for complete exome and transcriptome sequencing

    • NOTE: Patients who had sequencing under certain Mayo IRB protocols and neoantigens identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration
  • Negative pregnancy test ≤7 days prior to pre-registration for persons of childbearing potential only. If urine test cannot be confirmed negative, serum pregnancy test will be required.
  • Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle
  • ECOG PS of 0 or 1
  • Anticipated life expectancy > 6 months

PHASE II REGISTRATION:

  • Successful sequencing and production of REAL-Neo vaccine
  • Patients will receive >= 2 additional cycles of maintenance pembrolizumab
  • ECOG PS 0 or 1
  • Anticipated life expectancy > 6 months

  • The following lab values obtained =< 14 days prior to registration:

    • Hemoglobin >= 9.0 g/dl
    • ANC >= 1500/mm^3
    • Platelet count >= 100,000/mm^3
    • Total bilirubin =< 1.5 x ULN
    • ALT and AST =< 3 x ULN (=< 5 x ULN with liver involvement)
    • PT/INR and aPTT =< 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy
    • Calculated creatinine clearance >= 50 ml/min using Cockcroft-Gault formula
  • Provide written informed consent
  • Willing to provide blood specimens for research
  • Willing to return to enrolling institution for follow-up
  • Negative pregnancy test =< 14 days prior to registration for persons of childbearing potential only. If urine test cannot be confirmed negative, serum pregnancy test will be required.
  • Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle
  • Willing to receive tetanus vaccination if subject has not had one =< 1 year prior registration
  • Recovered from all toxicities associated with prior treatment to acceptable baseline status NCI CTCAE version 5.0 Grade of 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo)

Exclusion Criteria

ALL PHASES:

  • Any of the following because study involves investigational agent whose genotoxic, mutagenic and teratogenic effects on developing fetus and newborn are unknown:

    • Pregnant person
    • Nursing person unwilling to stop breast feeding
    • Person of childbearing potential unwilling to employ adequate contraception from registration through 6 months after final vaccine cycle
  • Co-morbid systemic illnesses or other severe concurrent disease which, in judgment of investigator, would make patient inappropriate for entry into this study or interfere significantly with proper assessment of safety and toxicity of prescribed regimens
  • History of myocardial infarction =< 6 months prior to pre-registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

PHASE I PRE-REGISTRATION:

  • Acute, reversible effect(s) of prior therapy not recovered to baseline regardless of interval since last treatment

  • Uncontrolled illness including, but not limited to:

    • Ongoing or active infection
    • Psychiatric illness/social situations
    • Congestive heart failure with New York Heart Association (NYHA) class III or IV moderate to severe objective evidence of cardiovascular disease
    • Stroke =< 3 months prior to pre-registration
    • Significant cardiac arrhythmia or unstable angina
    • Any other conditions that would limit compliance with study requirements
  • Receiving any other investigational agent which would be considered treatment for primary neoplasm, except pembrolizumab
  • Any prior hypersensitivity or adverse reaction to GM-CSF

  • Other active malignancy =< 3 years prior to pre-registration

    • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
    • NOTE: If there is history of prior malignancy, they must not be receiving other specific treatment for their cancer

  • History of active autoimmune disease (AD) that required systemic treatment in =< 30 days (i.e., use of disease modifying agents, corticosteroids > 10 mg daily prednisone equivalent, or other immunosuppressive drugs) prior to pre-registration

    • NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment. Patients with vitiligo, Graves disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with celiac disease controlled with diet modification are not excluded PHASE I REGISTRATION

  • Any of the following prior therapies:

    • Chemotherapy, experimental drugs (except pembrolizumab), or small molecules inhibitors (except for endocrine therapies) =< 3 weeks prior to registration
    • Radiation =< 2 weeks prior to registration
    • Major Surgery =< 4 weeks prior to registration
    • Received live vaccine =< 30 days prior to registration
    • Palliative radiation therapy for symptoms control including, but not limited to, bone metastatic lesion radiation therapy is allowed, but last dose of radiation therapy should be > 14 days from first dose of vaccination on study
  • CTCAE >= Grade 3 treatment-emergent adverse event (TEAE) to prior checkpoint inhibitor, TEAE requiring systemic corticosteroids (> 10 mg daily prednisone equivalent), or permanent treatment discontinuation due to toxicity
  • Neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or history of rhabdomyolysis
  • Active ADs that require chronic systemic steroids (> 10 mg daily prednisone equivalent) or immunosuppressive agents

  • Systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications =< 14 days prior to registration

    • NOTE: Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent permitted in absence of active AD

  • Evidence of leptomeningeal disease or central nervous system metastases that are untreated, symptomatic, or require steroids >10 mg daily prednisone equivalent

    • NOTE: Patients with history of stable treated brain metastases are eligible. Stable treated metastases defined as no evidence of progression for ≥4 weeks on brain imaging (MRI or CT scan)

PHASE II PRE-SCREENING:

  • Uncontrolled illness including, but not limited to:

    • Ongoing or active infection
    • Congestive heart failure with NYHA class III or IV; moderate to severe objective evidence of cardiovascular disease
    • Significant cardiac arrhythmia or unstable angina
    • Any other conditions that would limit compliance with study requirements
  • Any prior hypersensitivity or adverse reaction to GM-CSF

  • Other active malignancy =< 3 years prior to pre-screening

    • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
    • NOTE: If there is history of prior malignancy, they must not be receiving other specific treatment for their cancer

  • Known history of active AD that has required systemic treatment in the =< 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) prior to pre-screening

    • NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with Celiac disease controlled with diet modification are not excluded.

PHASE II PRE-REGISTRATION

  • Uncontrolled illness including, but not limited to:

    • Congestive heart failure with NYHA class III or IV; moderate to severe objective evidence of cardiovascular disease
    • Significant cardiac arrhythmia or unstable angina
    • Any other conditions that would limit compliance with study requirements
  • Any prior hypersensitivity or adverse reaction to GM-CSF

  • Other active malignancy =< 3 years prior to pre-registration

    • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
    • NOTE: If history of prior malignancy, must not be receiving other specific treatment for cancer

  • Known history of active AD that has required systemic treatment in the =< 30 days (i.e., with use of disease modifying agents, corticosteroids > 10 mg daily prednisone equivalent, or other immunosuppressive drugs) prior to pre-registration

    • NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid therapy for adrenal or pituitary insufficiency) is not considered systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with Celiac disease controlled with diet modification are not excluded.
  • Patients will also be excluded based on tissue/ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) quality and quantity. If any of the following quality and quantity thresholds are not met, patient will be excluded: (1) tumor tissue cellularity equal to or greater than 30%; (2) there are >= 2 cores with passing cellularity; (3) >= 30% of tumor RNA with fragment sizes are >= 200 base pairs (DV200 >= 30); (4) < 10% of DNA fragments are smaller than 1 kb; and (5) sufficient amount of both DNA (blood and tumor) and RNA (tumor) for exome sequencing and whole transcriptome sequencing (RNAseq) according to Mayo sequencing core. (Kits and technologies change overtime, so these are not fixed numbers.)

PHASE II REGISTRATION

  • Evidence of metastatic disease or recurrence

  • Any of the following prior therapies:

    • Chemotherapy, experimental drugs (except pembrolizumab), or small molecules inhibitors (except for endocrine therapies) =< 3 weeks prior to registration
    • Radiation =< 2 weeks prior to registration
    • Major surgery =< 4 weeks prior to registration

    • Received live vaccine =< 30 days prior to registration

      • NOTE: Continuation of pembrolizumab per standard of care is allowed
      • NOTE: Palliative radiation therapy for symptoms control including, but not limited to, bone metastatic lesion radiation therapy is allowed, but last dose of radiation therapy should be > 14 days from first dose of vaccination on study
  • CTCAE >= grade 3 TEAE to prior checkpoint inhibitor, TEAE requiring systemic corticosteroids (> 10 mg daily prednisone equivalent), or permanent treatment discontinuation due to toxicity
  • Neuromuscular disorders (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy), or history of rhabdomyolysis
  • Active ADs that require chronic systemic steroids (> 10 mg daily prednisone equivalent) or immunosuppressive agents

  • Requirement for systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications =< 14 days prior to registration

    • NOTE: Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1(cyclophosphamide, vaccine) ** NO LONGER ENROLLING **
NO LONGER ENROLLING Patients receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and on day 1 of cycle 2 in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy throughout the study. Additionally, patients undergo blood sample collection as well as CT or MRI throughout the study.
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
  • MRI
  • Magnetic Resonance Imaging Scan
  • MR
  • MRI Scan
  • NMR Imaging
  • NMRI
  • Medical Imaging
  • Magnetic Resonance / Nuclear Magnetic Resonance
  • nuclear magnetic resonance imaging
  • Magnetic Resonance Imaging (MRI)
  • sMRI
  • Magnetic resonance imaging (procedure)
  • MRIs
  • Structural MRI
Biological: Sargramostim
Given SC
Other Names:
  • 23-L-Leucinecolony-Stimulating Factor 2
  • DRG-0012
  • Leukine
  • Prokine
  • rhu GM-CFS
  • Sagramostim
  • Sargramostatin
Procedure: Computed Tomography
Undergo CT
Other Names:
  • CT
  • CAT
  • CAT Scan
  • Computerized Tomography
  • tomography
  • computerized axial tomography
  • CT scan
  • Computerized axial tomography (procedure)
  • Computed Axial Tomography (CAT)
  • Computerized Tomography (CT) scan
  • CTScan
Procedure: Biospecimen Collection
Undergo blood sample collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Blood Sample Collection
Drug: Cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719
Procedure: Biopsy
Undergo tissue biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Biological: Neoantigen Peptide Vaccine
Receive personalized neoantigen vaccine SC
Experimental: Cohort 2 (cyclophophamide, vaccine, pembrolizumab) ** NO LONGER ENROLLING **
NO LONGER ENROLLING Patients receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy throughout the study. Additionally, patients undergo blood sample collection as well as CT or MRI throughout the study.
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
  • MRI
  • Magnetic Resonance Imaging Scan
  • MR
  • MRI Scan
  • NMR Imaging
  • NMRI
  • Medical Imaging
  • Magnetic Resonance / Nuclear Magnetic Resonance
  • nuclear magnetic resonance imaging
  • Magnetic Resonance Imaging (MRI)
  • sMRI
  • Magnetic resonance imaging (procedure)
  • MRIs
  • Structural MRI
Biological: Sargramostim
Given SC
Other Names:
  • 23-L-Leucinecolony-Stimulating Factor 2
  • DRG-0012
  • Leukine
  • Prokine
  • rhu GM-CFS
  • Sagramostim
  • Sargramostatin
Procedure: Computed Tomography
Undergo CT
Other Names:
  • CT
  • CAT
  • CAT Scan
  • Computerized Tomography
  • tomography
  • computerized axial tomography
  • CT scan
  • Computerized axial tomography (procedure)
  • Computed Axial Tomography (CAT)
  • Computerized Tomography (CT) scan
  • CTScan
Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • Immunoglobulin G4
  • Pembrolizumab Biosimilar BCD-201
  • Pembrolizumab Biosimilar QL2107
  • QL2107
  • GME 751
  • Pembrolizumab Biosimilar GME751
Procedure: Biospecimen Collection
Undergo blood sample collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Blood Sample Collection
Drug: Cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719
Procedure: Biopsy
Undergo tissue biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Biological: Neoantigen Peptide Vaccine
Receive personalized neoantigen vaccine SC
Experimental: Cohort 3 (cyclophosphamide, vaccine, pembrolizumab)
Patients with TNBC receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle or as clinically indicated. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy throughout the study. Additionally, patients undergo blood sample collection as well as CT or MRI throughout the study.
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
  • MRI
  • Magnetic Resonance Imaging Scan
  • MR
  • MRI Scan
  • NMR Imaging
  • NMRI
  • Medical Imaging
  • Magnetic Resonance / Nuclear Magnetic Resonance
  • nuclear magnetic resonance imaging
  • Magnetic Resonance Imaging (MRI)
  • sMRI
  • Magnetic resonance imaging (procedure)
  • MRIs
  • Structural MRI
Biological: Sargramostim
Given SC
Other Names:
  • 23-L-Leucinecolony-Stimulating Factor 2
  • DRG-0012
  • Leukine
  • Prokine
  • rhu GM-CFS
  • Sagramostim
  • Sargramostatin
Procedure: Computed Tomography
Undergo CT
Other Names:
  • CT
  • CAT
  • CAT Scan
  • Computerized Tomography
  • tomography
  • computerized axial tomography
  • CT scan
  • Computerized axial tomography (procedure)
  • Computed Axial Tomography (CAT)
  • Computerized Tomography (CT) scan
  • CTScan
Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • Immunoglobulin G4
  • Pembrolizumab Biosimilar BCD-201
  • Pembrolizumab Biosimilar QL2107
  • QL2107
  • GME 751
  • Pembrolizumab Biosimilar GME751
Procedure: Biospecimen Collection
Undergo blood sample collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Blood Sample Collection
Drug: Cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719
Procedure: Biopsy
Undergo tissue biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Biological: Neoantigen Peptide Vaccine
Receive personalized neoantigen vaccine SC
Experimental: Cohort 4 (cyclophosphamide, vaccine, pembrolizumab)
Patients with NSCLC receive cyclophosphamide IV on day -3. Patients then receive personalized neoantigen vaccine with GM-CSF SC on days 1, 4, 8, and 15 of cycle 1 and then on day 1 of cycles 2, 5, and 8. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle or as clinically indicated. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy throughout the study. Additionally, patients undergo blood sample collection as well as CT or MRI throughout the study.
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
  • MRI
  • Magnetic Resonance Imaging Scan
  • MR
  • MRI Scan
  • NMR Imaging
  • NMRI
  • Medical Imaging
  • Magnetic Resonance / Nuclear Magnetic Resonance
  • nuclear magnetic resonance imaging
  • Magnetic Resonance Imaging (MRI)
  • sMRI
  • Magnetic resonance imaging (procedure)
  • MRIs
  • Structural MRI
Biological: Sargramostim
Given SC
Other Names:
  • 23-L-Leucinecolony-Stimulating Factor 2
  • DRG-0012
  • Leukine
  • Prokine
  • rhu GM-CFS
  • Sagramostim
  • Sargramostatin
Procedure: Computed Tomography
Undergo CT
Other Names:
  • CT
  • CAT
  • CAT Scan
  • Computerized Tomography
  • tomography
  • computerized axial tomography
  • CT scan
  • Computerized axial tomography (procedure)
  • Computed Axial Tomography (CAT)
  • Computerized Tomography (CT) scan
  • CTScan
Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • Immunoglobulin G4
  • Pembrolizumab Biosimilar BCD-201
  • Pembrolizumab Biosimilar QL2107
  • QL2107
  • GME 751
  • Pembrolizumab Biosimilar GME751
Procedure: Biospecimen Collection
Undergo blood sample collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Blood Sample Collection
Drug: Cyclophosphamide
Given IV
Other Names:
  • Cytoxan
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719
Procedure: Biopsy
Undergo tissue biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Biological: Neoantigen Peptide Vaccine
Receive personalized neoantigen vaccine SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of adverse events (Phase I)
Time Frame: Up to 2 years from first vaccine administration
The number and severity (grade) of all treatment related adverse events (AEs) will be tabulated and summarized. Non-hematologic AEs will be evaluated via the ordinal CTCAE v5.0 standard AE grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTCAE v5.0 standard AE grading. Both all grade and grade 3 and above AEs will be described and summarized in a similar fashion. Overall AE incidences as well as AE profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
Up to 2 years from first vaccine administration
Maximally tolerated dose (MTD) (Phase I)
Time Frame: Up to 2 years
MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients). A total of 6 patients treated at the MTD will be sufficient to identify common toxicities at the MTD. For instance, those toxicities with an incidence of at least 25% will be observed with a probability of at least 82% (1-(1-0.25).
Up to 2 years
Dose LImiting Toxicity (DLT) (Phase I)
Time Frame: Up to 2 years
DLT are defined to be adverse event (AE) occurring from day -3 through day 35 that is possibly, probably, or definitely related to neoantigen peptide vaccine with/without pembrolizumab and fulfills any of the following criteria using the National Cancer Institute's Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version (v) 5.0
Up to 2 years
Event free survival (EFS) (Phase II Cohort 3)
Time Frame: Up to 2 years
EFS is defined as the length of time after primary treatment for a cancer ends until occurrence of complications or events that the treatment was intended to prevent or delay.
Up to 2 years
Disease-free survival (DFS) (Phase II Cohort 4)
Time Frame: Up to 2 years
DFS is defined as the length of time after primary treatment for a cancer ends until any signs or symptoms of that cancer recur.
Up to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number and percentage of participants who completed the sequencing with satisfactory data quality registration and identified at least 10 actionable peptides, meet the eligibility criteria for registration, and able to initiate vaccine production
Time Frame: Up to 16 weeks
Feasibility will be defined as the number and percentage of participants who completed the sequencing with satisfactory data quality registration and identified at least 10 actionable peptides, meet the eligibility criteria for registration, and able to initiate vaccine production within 16 weeks.
Up to 16 weeks
Immunogenicity responders
Time Frame: Within 24 weeks
The number and percentage of patients who are vaccine immunity responders will be calculated. The immunity responder for each patient is defined as >= 20% of neoantigens formulated into vaccine with at least 3-fold of value increase at any timepoint,
Within 24 weeks
Incidence of adverse events (Phase II)
Time Frame: Up to 2 years
Will be assessed using CTCAE v5.0. Defined as the proportion of patients experienced at least one grade 3, grade 4, or grade 5 of each type of AE during the protocol defined treatment. The binary endpoints will be estimated, in each cohort (or by dose level. Dose intensity and number of cycles will be summarized by mean, standard deviation, median, Q1, Q3, and range, in each cohort. The maximum grade for each type of adverse events that are possibly, probably, or definitely related to study treatments will be recorded for each patient. The frequency tables will be reviewed to determine the patterns.
Up to 2 years
Immunogenicity response rate (Phase I)
Time Frame: Within 24 weeks
Will be defined as number of patients who have ≥ 20% of neoantigens formulated into vaccine with at least 3-folds of value increase at any timepoint within 24 weeks, divided by total number of evaluable patients. Evaluable patients are defined as patients who are properly registered and received at least one dose of vaccine.
Within 24 weeks
Immunogenicity response rate (Phase II)
Time Frame: Within 24 weeks
Will be defined as number of patients who have ≥ 20% of neoantigens formulated into vaccine with at least 3-folds of value increase at any timepoint within 24 weeks, divided by total number of evaluable patients. Evaluable patients are defined as patients who are properly registered and received at least one dose of vaccine.
Within 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (Phase I)
Time Frame: Within 12 weeks
Will be defined as number of patients who achieve complete response or partial response per Response Evaluation Criteria in Solid Tumors criteria version 1.1, confirmed based on at least two consecutive evaluations with 6 weeks apart or at the next re-staging computed tomography scan determined by treating physician, divided by total number of evaluable patients.
Within 12 weeks
Persistence Immunogenicity response rate (Phase I and Phase II)
Time Frame: Within 24 weeks from baseline
Will be defined as number of patients who have as at least 3-folds of value increase of any neoantigen from baseline at 12 months among neoantigens that had been detected with at least 3-folds of value increase within 24 weeks from baseline, divided by total number of evaluable patients.
Within 24 weeks from baseline
Pre-existing Immunity (Phase I and Phase II)
Time Frame: Within 24 weeks from baseline
Will be defined as number of patients with mean antigen-specific T cell frequency is statistically higher (P<0.05) from no antigen wells at baseline, divided by total number of evaluable patients.
Within 24 weeks from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Investigators

  • Principal Investigator: Yanyan Lou, MD, PhD, Mayo Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 31, 2022

Primary Completion (Estimated)

March 31, 2028

Study Completion (Estimated)

March 31, 2028

Study Registration Dates

First Submitted

February 25, 2022

First Submitted That Met QC Criteria

February 25, 2022

First Posted (Actual)

March 8, 2022

Study Record Updates

Last Update Posted (Actual)

March 12, 2026

Last Update Submitted That Met QC Criteria

March 10, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MC210102
  • NCI-2022-01258 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • 21-008509 (Other Identifier: Mayo Clinic Institutional Review Board)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Renal Cell Carcinoma

Clinical Trials on Magnetic Resonance Imaging

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe